Clinical Trial: Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title:

Brief Summary: A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).

Detailed Summary:
Sponsor: Allergan

Current Primary Outcome: Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye [ Time Frame: Baseline, Day 3 ]

UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved. The percentages of patients with at least a 2 or more line improvement in UNVA in the non-dominant eye are presented.


Original Primary Outcome: Percentage of Participants with at Least a 2 Line Improvement from Baseline in Uncorrected Near Visual Acuity (UNVA) [ Time Frame: Baseline, Day 3 ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Allergan

Dates:
Date Received: July 21, 2014
Date Started: July 2014
Date Completion:
Last Updated: October 30, 2015
Last Verified: October 2015